Table 1.
Baseline characteristics among overall patient population and among complete responders and non-responders
| Overall | Complete responders (n = 15) | Non-responders (n = 5) | |
|---|---|---|---|
| Age (years, median) | 20 | 20.5 | 18 |
| 0–10 (n) | 1 | 1 | 0 |
| 10–20 (n) | 9 | 5 | 4 |
| 20–30 (n) | 9 | 7 | 1 |
| 30–40 (n) | 1 | 1 | 0 |
| > 40 (n) | 1 | 1 | 0 |
| Sex (n, %) | |||
| Male | 7 (33) | 6 (40) | 1 (20) |
| Female | 14 (67) | 9 (60) | 3 (80) |
| Splenectomised (n, %) | 3 (14) | 3 (20) | 0 |
| Thalidomide starting dose (n, %) | |||
| 50 mg OD | 7 (33) | 7 | 0 |
| 100 mg OD | 14 (67) | 8 | 4 |
| Thalidomide final dose (n, %) | |||
| 50 mg OD | 4 (19) | 2 | 1 |
| 100 mg OD | 17 (81) | 13 | 3 |
| Spleen Size, Baseline, (cms) (median, range) | 4 (0–18) | 7 (0–18) | 5.5 (0–10) |
| Ferritin, Baseline (ng/ml), (median, range) | 2405.67 (131–10,250) | 1919 (131–6649) | 3931(862–10,250) |